Menu Search
Equities

Scienture Holdings Inc

4E4:BER

Scienture Holdings Inc

Actions
  • Price (EUR)7.71
  • Today's Change-0.192 / -2.43%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Scienture Holdings, Inc., formerly TRxADE Health, Inc., is a comprehensive health services and pharmaceutical product company focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs, optimize the prescription journey and patient engagement in the United States. It operates through Scienture, LLC and Integra Pharma Solutions, LLC. Scienture, LLC is a branded specialty pharmaceutical company. Its assets in development are across therapeutics areas, indications and cater to different market segments. Its products include SCN - 102 (Cardiovascular), SCN - 104 (CNS-Pain), SCN - 105 (CNS), SCN - 106 (Cardiovascular) and SCN - 107 (Pain). Integra Pharma Solutions, LLC is the pharmaceutical supplier of choice for healthcare organizations of all sizes. Its expertise in the distribution of products extends to all healthcare markets including government organizations, hospitals, clinics, and independent pharmacies nationwide.

  • Revenue in USD (TTM)4.43m
  • Net income in USD-20.15m
  • Incorporated2005
  • Employees8.00
  • Location
    Scienture Holdings Inc2420 Brunello TraceLUTZ 33558United StatesUSA
  • Phone+1 (813) 601-3533
  • Fax+1 (800) 253-5177
  • Websitehttps://www.trxadehealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.